Establish treatment options sooner with EasyM™
Our test has been extensively validated and is pending certification. We welcome caregivers, clinical labs, and pharmaceutical industries to partner or collaborate with us to expedite the development of our assay so we can meet the need of a highly sensitive and non-invasive assessment of disease for MM patients.
EasyM™ exploits both MS-based protein sequencing and quantification technologies enhanced by machine learning algorithms, to track the M-protein and provide truly personalized monitoring.
Home to Canada’s largest privately-owned MS proteomics facility, our team has over two decades of experience in MS-based proteomics and Big Data-driven machine learning data analysis.